Type 2 Diabetes Trial, Recruiting (NCT05933161)

Type 2 Diabetes Trial, Recruiting NCT05933161 Sponsor: Mayo Clinic Condition: Type 2 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT05933161 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 2 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have had a specific type of heart pump (called an LVAD — either a HeartWare or HeartMate 3 device) implanted at any point after 2010
You have been diagnosed with Type 2 diabetes
You are currently taking any medication or treatment to manage your blood sugar levels
It has been more than 3 months since your heart pump was implanted
You are able to use a smartphone with an app called "LibreLink" to share your blood sugar readings
You may still be eligible if you are already using a continuous glucose monitor (a small device that tracks your blood sugar automatically)

Who may not be able to join:

You have Type 1 diabetes (rather than Type 2)
You are not able to come back for a follow-up appointment at the 3-month mark
You do not wish to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Andrew Rosenbaum, MD, Mayo Clinic

Phone: (507) 293-1375

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05933161

Sponsor: Mayo Clinic

Phase: Not Applicable

Status: Recruiting

Condition: Type 2 Diabetes

Trial contact: (507) 293-1375

More information: https://clinicaltrials.gov/study/NCT05933161

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have had a specific type of heart pump (called an LVAD — either a HeartWare or HeartMate 3 device) implanted at any point after 2010
You have been diagnosed with Type 2 diabetes
You are currently taking any medication or treatment to manage your blood sugar levels
It has been more than 3 months since your heart pump was implanted
You are able to use a smartphone with an app called "LibreLink" to share your blood sugar readings
You may still be eligible if you are already using a continuous glucose monitor (a small device that tracks your blood sugar automatically)

Who may not be able to join:

You have Type 1 diabetes (rather than Type 2)
You are not able to come back for a follow-up appointment at the 3-month mark
You do not wish to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Mayo Clinic

Registry

ClinicalTrials.gov

Start date

10 November 2023

Est. completion

1 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Average glucose values based on continuous glucose monitoring; Estimated average glucose (eAG) values based on hemoglobin-A1c lab values; Estimated average glucose (eAG) values based on fructosamine lab values

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov